Barr Gets Tentative OK For Narcolepsy Drug

Tomas Thorne

Basic

Last Updated: February 20, 2023

Narcolepsy Drug

Research Based

ResearchPeptides.org follows the strictest sourcing guidelines in the health and nootropics industry. Our focus is to exclusively link to peer-reviewed studies found on respected websites, like PubMed. We focus on finding the most accurate information from the scientific source.

Our goal is to provide you with the most scientifically accurate, unbiased, and comprehensive information regarding all research peptides and SARMs.

All of our content is written by people with a strong science background, including medical researchers.

Our content is continually monitored by an internal peer-review process to ensure accuracy. We strive to never have a piece of inaccurate information on this website.

If you feel that any of our content is inaccurate or out-of-date, please contact us at: [email protected]

By DAVID SCHEPP
THE JOURNAL NEWS

Barr Pharmaceuticals Inc. reported yesterday that it has received preliminary approval from the Food and Drug Administration to market a generic form of Modafinil tablets used to treat narcolepsy, a disease characterized by excessive daytime sleepiness.
Pomona-based Barr filed an application with the FDA in December 2002 to begin selling Modafinil 100 milligram and 200 milligram tablets.

Barr spokeswoman Carol Cox said the generic-drug maker won’t have a product on the market any time soon because the application is subject to litigation.

Cephalon Inc., the maker of Provigil, the brand name for Modafinil, alleges Barr infringed its patent on the drug. A trial is scheduled for next January in the U.S. District Court of New Jersey.

Modafinil had annual sales of about $289 million, as of Nov. 30.

References

Table of Contents
    Add a header to begin generating the table of contents